Ozempic (semaglutide) highlights of prescribing information, Food and Drug Administration (2025) FDA approves Ozempic (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk USA (2025) Alcohol-associated liver disease, Johns Hopkins Medicine (2025) Nonalcoholic fatty liver disease (NAFLD) & NASH, National Institute of Diabetes and Digestive and Kidney Diseases (2021) Symptoms & causes of NAFLD & NASH, National Institute of Diabetes and Digestive and Kidney Diseases (2021) Efficacy and safety of semaglutide in non-alcoholic fatty liver disease, World Journal of Gastroenterology (2023) Role of semaglutide in the treatment of nonalcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis, Diabetes & Metabolic Syndrome: Clinical Research & Reviews (2023) GLP-1 receptor agonists in non-alcoholic fatty liver disease: Current evidence and future perspectives, International Journal of Molecular Sciences (2023) AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease, Hepatology (2023) Rezdiffra (resmetirom) highlights of prescribing information, Food and Drug Administration (2024) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Unlike mTORC1, mTORC2 is less nutrient-sensitive and is instead heavily modulated by growth factors
Patentability and Funding: The commercial development of BPC-157 will also depend on navigating patent landscapes
All State and Union Territory drug controllers have also been asked to actively monitor print, electronic, digital, social-media, and outdoor platforms for non-compliant advertisements or surrogate promotional activities relating to these drugs
Retatrutide produced clinically meaningful reductions in HbA1c across the dose range alongside body-weight loss of about 17% at the top dose, with a safety profile in line with GLP-1 and dual GIP/GLP-1 agonists [2]
Safety, tolerability, pharmacokinetics, and clinical outcomes following treatment of painful knee osteoarthritis with senolytic molecule UBX0101
